工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向新抗原的 TCR-T 细胞治疗实体瘤：距离临床应用还有多远
英文原题：Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application.
查看英文原题
Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向新抗原的T细胞受体工程T（TCR-T）细胞在实体瘤免疫治疗方面具有潜力。随着整个生产流程的不断优化，TCR-T细胞的制造工艺正变得越来越高效和高产。然而，TCR-T细胞的临床规模生产仍面临巨大挑战。在此，我们总结了靶向新抗原的TCR-T细胞疗法的最新进展，并重点关注制备个体化靶向新抗原的TCR-T细胞的技术难点以及临床应用中的挑战。本综述还讨论了改进TCR-T细胞疗法的可能途径。
展开英文摘要原文
T cell receptor-engineered T (TCR-T) cells targeting neoantigens present potential immunotherapy for solid tumors. With the continuous optimization of the entire production procedures, the manufacturing process of TCR-T cells is becoming more efficient and productive.
However, clinical-scale manufacturing of TCR-T cells still encounters tremendous challenges.
Here, we summarize the latest progress of neoantigen-targeted TCR-T cell therapy and focus on the technical difficulties in preparing personalized neoantigen-targeted TCR-T cells and the challenges in clinical applications. Possible approaches for improving TCR-T cell therapy are discussed as well in this review.
论文信息
- 作者
- Xu R、Du S、Zhu J、Meng F、Liu B
- 第一作者单位
- The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China.China
- 通讯作者单位
- The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China. Electronic address: baoruiliu@nju.edu.cn.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cancer letters2022 Oct 10
- 原文标识
- PubMed 35921969 · DOI 10.1016/j.canlet.2022.215840